Symptoms:
Mild fatigue, some abdominal discomfort, and occasional night sweats. Jane reports her symptoms are tolerable, but she feels something is wrong. MPN-SAF TSS: 15 (low)1,2
For US Healthcare Professionals Only
This profile represents a hypothetical patient.
56-year-old1 executive assistant
Mild fatigue, some abdominal discomfort, and occasional night sweats. Jane reports her symptoms are tolerable, but she feels something is wrong. MPN-SAF TSS: 15 (low)1,2
Spleen palpable 5 cm below LCM1
Intermediate-1 (due to her constitutional symptoms)3
Is Jane really feeling OK?
She has considerable symptoms and her spleen volume is increasing, which may impact overall survival3,4
Spleen volume and risk of death
Increasing spleen volume is associated with a 14% increase in mortality risk4
In a study of 1054 patients with primary MF†
9 out of 10 had a palpable spleen at diagnosis5
CI=confidence interval; COMFORT=COntrolled MyeloFibrosis study with ORal JAK inhibitor Treatment; CT=computed tomography; DIPSS=Dynamic International Prognostic Scoring System; ELN=European LeukemiaNet; HR=hazard ratio; IWG-MRT=International Working Group-Myeloproliferative Neoplasms Research and Treatment; JAK=Janus kinase; LCM=left costal margin; MF=myelofibrosis; MPN-SAF=Myeloproliferative Neoplasm Symptom Assessment Form; MRI=magnetic resonance imaging; OS=overall survival; SVR=spleen volume reduction; TSS=Total Symptom Score.
References: 1. Verstovsek S, Mesa RA, Gotlib J, et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med. 2012;366(9):799-807. Supplemental appendix available at: https://www.nejm.org/doi/full/10.1056/nejmoa1110557. 2. Emanuel RM, Dueck AC, Geyer HL, et al. Myeloproliferative neoplasm (MPN) symptom assessment form total symptom score: prospective international assessment of an abbreviated symptom burden scoring system among patients with MPNs. J Clin Oncol. 2012;30(33):4098-4103. 3. Passamonti F, Cervantes F, Vannucchi AM, et al. A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment). Blood. 2010;115(9):1703-1708. 4. Vannucchi AM, Kantarjian HM, Kiladjian J-J, et al; on behalf of the COMFORT Investigators. A pooled analysis of overall survival in COMFORT-I and COMFORT-II, 2 randomized phase III trials of ruxolitinib for the treatment of myelofibrosis. Haematologica. 2015;100(9):1139-1145. Supplemental information available at: https://doi.org/10.3324/haematol.2014.119545. 5. Cervantes F, Dupriez B, Pereira A, et al. New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood. 2009;113(13):2895-2901. 6. Tefferi A, Cervantes F, Mesa R, et al. Revised response criteria for myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report. Blood. 2013;122(8):1395-1398. 7. Harrison CN, Vannucchi AM, Kiladjian J-J, et al; on behalf of the COMFORT-II investigators. Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis. Leukemia. 2016;30(8):1701-1707.
JAKAFI®/JAKAFI XR™ (ruxolitinib) is for treatment of intermediate or high‑risk myelofibrosis (MF), including primary MF, post–polycythemia vera MF and post–essential thrombocythemia MF in adults.
JAKAFI/JAKAFI XR is for treatment of polycythemia vera (PV) in adults who have had an inadequate response to or are intolerant of hydroxyurea.
JAKAFI/JAKAFI XR is for treatment of steroid‑refractory acute graft‑versus‑host disease (aGVHD) in adult and pediatric patients 12 years and older.
JAKAFI/JAKAFI XR is for treatment of chronic graft‑versus‑host disease (cGVHD) after failure of one or two lines of systemic therapy in adult and pediatric patients 12 years and older.
Please see Full Prescribing Information for JAKAFI/JAKAFI XR.